The ultra-low-cost Vayu-bCPAP device allows for precise delivery of oxygen concentration, flow, and pressure that can dramatically improve the outcomes of newborns and infants worldwide.
In addition, the device provides an alternative treatment for newborns and infants undergoing CPAP using ventilators. When Vayu-bCPAP is used, ventilators can be freed up for adult COVID-19 patients. Because of this, the device has been granted FDA Emergency Use Authorization to help in the fight against COVID-19
Our long-term business model is to provide devices at cost to resource-limited regions worldwide and to compete with the CPAP markets in advanced countries. Vayu-bCPAP has the potential for large global impact.